Form 4 Filing for ARS Pharmaceuticals, Inc. - Insider Transaction

This filing details a Form 4 submission for ARS Pharmaceuticals, Inc. (SPRY) concerning an insider transaction by director Brent L. Saunders. On June 24, 2026, Mr. Saunders acquired 30,000 shares through the exercise of a stock option at a price of $0.00 per share. These options are exercisable for the underlying Common Stock. The acquired shares will vest in full on the earlier of June 24, 2027, or the date of the Issuer's 2027 annual meeting of stockholders. Following this transaction, Mr. Saunders holds 30,000 shares. The filing was signed by Kathleen Scott as Attorney-in-Fact on June 26, 2026.